文献速递神经创伤神经重症

抗高迁移率族蛋白B1抗体治疗可能预防创伤性脑损伤后的认知功能障碍

Anti-High Mobility Group Box 1 Antibody Therapy May Prevent Cognitive Dysfunction After Traumatic Brain Injury.
PubMed 文献 · World Neurosurg · 2018-11-02

本研究在大鼠液压冲击脑损伤模型中,于伤后静脉给予抗高迁移率族蛋白B1(HMGB1)单克隆抗体或对照抗体,2周后评估组织化学染色、血浆HMGB1水平、运动与记忆功能及视频脑电图。结果显示抗HMGB1单抗减轻同侧皮质活化小胶质细胞聚集、防止同侧海马神经元死亡、抑制HMGB1转位并改善运动功能,其对运动与认知功能的益处持续至伤后14天,对脑电活动亦有积极作用。作者认为抗HMGB1单抗在亚急性期仍有益处,可能预防创伤性脑损伤后认知功能障碍。

要点

  • 大鼠液压冲击脑损伤后静脉给予抗HMGB1单克隆抗体,可减轻同侧皮质活化小胶质细胞聚集。
  • 抗HMGB1单克隆抗体可防止同侧海马神经元死亡,并抑制HMGB1转位、改善运动功能。
  • 抗HMGB1单克隆抗体对运动与认知功能的益处持续至伤后14天,对脑电活动亦有积极作用。

核心结论

  • 抗HMGB1单克隆抗体的有益作用在伤后亚急性期持续存在,提示其可能预防创伤性脑损伤后的认知功能障碍。

研究设计与样本

  • 研究采用大鼠液压冲击模型诱导创伤性脑损伤,伤后静脉给予抗HMGB1单克隆抗体或对照单克隆抗体。
  • 伤后2周评估组织化学染色、血浆HMGB1水平、运动活动与记忆以及视频脑电图监测。

主要发现

  • 抗HMGB1单克隆抗体显著减轻创伤性脑损伤后同侧大脑皮质活化小胶质细胞的聚集。
  • 抗HMGB1单克隆抗体防止创伤性脑损伤后同侧海马神经元死亡。
  • 抗HMGB1单克隆抗体治疗抑制HMGB1转位并减轻运动功能损害。
  • 抗HMGB1单克隆抗体对运动与认知功能的益处持续至伤后14天。
  • 抗HMGB1单克隆抗体治疗对脑电图活动亦有积极作用。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High mobility group box 1 (HMGB1) protein plays a key role in triggering inflammatory responses in many diseases. Our previous study showed that HMGB1 is found upstream of secondary damage in traumatic brain injury (TBI). We found that anti-HMGB1 monoclonal antibody (mAb) effectively decreased acute brain damage, including the disruption of the blood-brain barrier, brain edema, and neurologic dysfunction. This effect of anti-HMGB1 mAb lasts for at least 1 week. In this study, we explored subacute effects of anti-HMGB1 mAb after TBI. METHODS: TBI was induced in rats by fluid percussion. Anti-HMGB1 mAb or control mAb was given intravenously after TBI. Histochemical staining, plasma levels of HMGB1, motor activity and memory, and video electroencephalography monitoring were evaluated 2 weeks after fluid percussion injury. RESULTS: Anti-HMGB1 mAb remarkably attenuated accumulation of activated microglia in the rat cortex in the ipsilateral hemisphere after TBI. Anti-HMGB1 mAb also prevented neuronal death in the hippocampus in the ipsilateral hemisphere after TBI. Treatment of rats with anti-HMGB1 mAb inhibited HMGB1 translocation and suppressed impairment of motor function. The beneficial effects of anti-HMGB1 mAb on motor and cognitive function persisted for 14 days after injury. Treatment with anti-HMGB1 mAb also had positive effects on electroencephalography activity. CONCLUSIONS: The beneficial effects of anti-HMGB1 mAb continued during the subacute postinjury phase, suggesting that anti-HMGB1 mAb may prevent cognitive dysfunction after TBI.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Okuma Y, Wake H, Teshigawara K, et al. Anti-High Mobility Group Box 1 Antibody Therapy May Prevent Cognitive Dysfunction After Traumatic Brain Injury. World Neurosurg. 2018. PMID: 30391757. doi:10.1016/j.wneu.2018.10.164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。